{"id":"W4226197684","doi":"10.1177/13524585221083194","title":"Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years","year":2022,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":47,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"Sanofi Genzyme; Innosuisse - Schweizerische Agentur für Innovationsförderung; European Commission; Sanofi; Bayer HealthCare; Eli Lilly and Company; CSL Behring; Biogen; Merck KGaA; Teva Pharmaceutical Industries; Novartis; Pfizer; National Research Foundation","keywords":"Medicine; Placebo; Hazard ratio; Internal medicine; Multiple sclerosis; Confidence interval; Pathology; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003453355,0.0006458127,0.001475698,0.0004101936,0.000288319,0.0004956999,0.0003640538,0.0005913007,0.001805134],"category_scores_gemma":[0.001965092,0.0001973251,0.001352479,0.0004419004,0.000412626,0.0006114999,0.0004071254,0.000940717,0.0003452608],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003752121,"about_ca_system_score_gemma":0.0007194781,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004108259,"about_ca_topic_score_gemma":0.0009825807,"domain_scores_codex":[0.9993424,0.0002935855,0.00007206193,0.0001039201,0.0001125193,0.00007548468],"domain_scores_gemma":[0.9975472,0.0005376,0.0009496038,0.0003102903,0.000214357,0.0004409316],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7135045,0.007588036,0.1331534,0.001560049,0.006390157,0.0004170465,0.0004259093,0.00186077,0.02230099,0.0001391434,0.001825083,0.1108349],"study_design_scores_gemma":[0.08234789,0.2558163,0.6460121,0.0001798998,0.005109817,0.0007286664,0.0001289648,0.001314172,0.004994651,0.0002189133,0.00307658,0.00007208681],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9966073,0.001786296,0.0001003328,0.00004406025,0.000009688836,0.0001850387,0.0007907116,0.00001481006,0.0004616941],"genre_scores_gemma":[0.9963844,0.0006524686,0.000252498,0.00009410805,0.0000472493,0.0002235131,0.001919918,0.000004898176,0.0004210061],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003453355,"threshold_uncertainty_score":0.01826334,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04661293181743509,"score_gpt":0.2567185930640929,"score_spread":0.2101056612466579,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}